Literature DB >> 10885641

Clozapine augmentation: safety and efficacy.

S A Chong1, G Remington.   

Abstract

While clozapine has been demonstrated to be efficacious in refractory schizophrenia and possibly schizoaffective as well as bipolar disorders, a substantial number of patients still remain unresponsive. One strategy in treating these refractory patients is to augment clozapine with other somatic treatments. This article reviews the efficacy and safety of the combination of clozapine with other somatic treatments. A total of 70 articles were obtained from a manual, as well as computerized (Medline), search of the English language literature from 1978 to March 1998. Few controlled studies exist; most were case reports/series. From these data, the greatest risk of adverse effects seems to be associated with clozapine combined with benzodiazepines, valproate, or lithium, but no currently evaluated combination is absolutely unsafe. In terms of efficacy, the data suggest a number of potential augmentation strategies, although controlled data are few. Combination therapies with clozapine are common in clinical practice, despite a lack of empirical data, and the benefits and risks of these combinations need to be systematically reviewed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10885641     DOI: 10.1093/oxfordjournals.schbul.a033463

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  9 in total

1.  Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.

Authors:  Deanna L Kelly; Robert R Conley; Stephanie Feldman; Yang Yu; Robert P McMahon; Charles M Richardson
Journal:  Psychiatr Q       Date:  2006

Review 2.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

Review 3.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Authors:  Iris E Sommer; Marieke J H Begemann; Anke Temmerman; Stefan Leucht
Journal:  Schizophr Bull       Date:  2011-03-21       Impact factor: 9.306

Review 5.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 6.  Risperidone augmentation of clozapine: a critical review.

Authors:  Vassilis P Kontaxakis; Panayotis P Ferentinos; Beata J Havaki-Kontaxaki; Konstantinos G Paplos; Dimitra A Pappa; George N Christodoulou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-08       Impact factor: 5.270

7.  Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies.

Authors:  Tian-Mei Si; Yun-Shu Zhang; Liang Shu; Ke-Qing Li; Xie-He Liu; Qi-Yi Mei; Gao-Hua Wang; Pei-Shen Bai; Li-Ping Ji; Xian-Sheng Cheng; Cui Ma; Jian-Guo Shi; Hong-Yan Zhang; Hong Ma; Xin Yu
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

8.  Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital.

Authors:  Wenying Yi; Shenglin She; Jie Zhang; Haibo Wu; Yingjun Zheng; Yuping Ning
Journal:  Neuropsychiatr Dis Treat       Date:  2020-11-24       Impact factor: 2.570

9.  Prescription attitudes and practices regarding clozapine among Serbian psychiatrists: results of a nationwide survey.

Authors:  Dragana Ignjatovic Ristic; Dan Cohen; Ivan Ristic
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.